Edigene Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
Jan 2040
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Aug 13, 2027The maintenance fee for Tale RVD Specifically Recognizing DNA Base Modified by Methylation and Application Thereof (US 11,897,920) comes due Aug 13, 2027. Unpaid by Feb 14, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
Showing 1 to 1 of 1
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,897,920 | Tale RVD Specifically Recognizing DNA Base Modified by Methylation and Application Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 pending · 8 abandoned · 1 no status recorded
Showing 1 to 10 of 10, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 18/270,181 | Dec 28, 2021 | No status recorded | |
| 17/226,961 | Methods and Compositions for Editing Rnas | Apr 9, 2021 | Abandoned |
| 17/640,759 | Method for Evaluating Gene Editing Therapy Based on Off-Target Assessment | Sep 4, 2020 | Abandoned |
| 17/607,796 | Method for Predicting Effectiveness of Treatment of Hemoglobinopathy | Apr 29, 2020 | Abandoned |
| 17/603,918 | Methods and Compositions for Editing Rnas | Apr 15, 2020 | Abandoned |
| 17/593,811 | Method for Identifying Functional Elements | Mar 26, 2020 | Abandoned |
| 17/284,232 | Methods and Compositions for Editing Rnas | Oct 12, 2019 | Pending |
| 16/758,824 | Method for Increasing Fetal Hemoglobin Expression Level | Oct 26, 2018 | Abandoned |
| 16/758,704 | Method for Improving Fetal Hemoglobin Expression | Oct 26, 2018 | Abandoned |
| 16/648,567 | Gene Editing T Cell and Use Thereof | Sep 18, 2018 | Abandoned |